Navigation Links
First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
Date:1/13/2009

SAN CARLOS, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that dosing has started in a Phase 2 clinical trial of NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals have also been obtained and dosing will begin shortly in two additional trials: a randomized Phase 2 study to evaluate NKTR-102 versus irinotecan in second-line colorectal cancer patients with the KRAS gene mutation, and a Phase 2 study in metastatic breast cancer. Nektar has also received Institutional Review Board (IRB) approval for a Phase 2 cervical cancer study of NKTR-102.

"NKTR-102 is an excellent example of how Nektar's advanced polymer conjugate technology platform allowed us to precisely modify a cytotoxic agent with sub-optimal pharmacokinetics and enhance its therapeutic profile," said Randall Moreadith, M.D., Ph.D., Senior Vice President and Chief Development Officer of Nektar. "We are excited to have dosed our first patient in the start of our expanded Phase 2 clinical development program. NKTR-102 is a novel oncolytic that has the potential to dramatically expand therapeutic options for oncologists and improve survival rates for patients with a variety of cancers."

Using its proprietary polymer conjugate technology platform, Nektar is the first company to have created a small molecule PEGylated drug conjugate that has demonstrated therapeutic activity in patients. In addition to the Phase 2 clinical studies in breast, ovarian, cervical and colorectal cancers, a Phase 2a study evaluating NKTR-102 in combination with cetuximab has completed enrollment and full results of this study are expected to be available in the first half of 2009.

About the NKTR-102 Phase 2 Study Designs

The NKTR-102 Phase 2 randomized trial will evaluate the efficacy
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 2009 Marks 50 Years of Innovative Firsts for Instrumentation Laboratory
2. Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase
3. The IN VIVO Blog Selects First Annual Deal of the Year
4. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
5. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
6. First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform
7. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
8. USC researchers derive first embryonic stem cells from rats
9. ASP Announces Availability of EVOTECH(TM) Endoscope Cleaner and Reprocessor - First Commercially Available System to Eliminate Manual Cleaning of Endoscopes
10. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
11. Bioamber announces worlds first bio-based succinic acid plant: helping to reduce dependence on fossil fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
(Date:1/14/2014)... 2014 Holloway America today announced an ... test reports (MTRs) for all pressure vessels and tank ... is particularly important for equipment that must meet ASME, ... features search functionality that allows authorized users to quickly ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... JOLLA, Calif., Nov. 22, 2011  If algae is to be ... workers are needed to make that a reality. Applications are ... California San Diego to retrain workers as general science technicians ... and Imperial County region. Approximately 55 students ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... Company,s participation at the 23rd Annual Piper Jaffray Healthcare Conference ... 2011. Ronald M. Lindsay, Ph.D., Director and ... will present on Tuesday, November 29, 2011 beginning at 8:30 ...
... Among the many hurdles to be cleared before human embryonic ... or not transplanted cells can functionally integrate into target organs ... Proceedings of the National Academy of Sciences, a ... lab from blank slate human embryonic stem cells and implanted ...
Cached Biology Technology:Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 3Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference 2Implanted neurons, grown in the lab, take charge of brain circuitry 2Implanted neurons, grown in the lab, take charge of brain circuitry 3
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... modeling study suggests that fish consumption advisories for ... to long-lived contaminants like persistent organic pollutants (POPs). ... of researchers including University of Toronto Scarborough PhD ... at how different levels of environmental contamination, a ... chemicals in the body influenced exposure in her ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2
... Sharing is a behavior on which day care workers and kindergarten ... for our ape cousins the bonobos, sharing just comes naturally. ... Current Biology, it looks like bonobos never seem to ... notorious for hogging food to themselves, by physical aggression if necessary. ...
... Imagine that you are emerging from the subway and heading ... in the wrong direction. For a moment, you feel disoriented, ... surrounding streets quickly helps you pinpoint your location, and you ... Research tells us that human adults, toddlers, rats, chicks ...
... the first to design a bioactive nanomaterial that promotes the ... of expensive growth factors. Minimally invasive, the therapy activates the ... therapy can do this. The results will be published ... of the National Academy of Sciences (PNAS). "Unlike ...
Cached Biology News:'Peter Pan' apes never seem to learn selfishness 2'Peter Pan' apes never seem to learn selfishness 3Ability to navigate may be linked to genes, researcher says 2Ability to navigate may be linked to genes, researcher says 3Growing cartilage -- no easy task 2
Hybridization Buffer 3.6 ml...
Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Biology Products: